Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Key Points

• Zurcher Kantonalbank Zurich Cantonalbank significantly reduced its stake in Lantheus Holdings, Inc. by 88.3%, selling 310,351 shares during the first quarter.
• Institutional investors and hedge funds now own 99.06% of Lantheus's stock, indicating strong institutional interest in the company.
• Despite missing earnings expectations, Lantheus Holdings reported a 0.8% increase in revenue year-over-year for the last quarter.

Zurcher Kantonalbank Zurich Cantonalbank lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 88.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,298 shares of the medical equipment provider's stock after selling 310,351 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.06% of Lantheus worth $4,031,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Janus Henderson Group PLC increased its holdings in shares of Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after acquiring an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after acquiring an additional 435,445 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after acquiring an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC increased its holdings in shares of Lantheus by 39.1% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after acquiring an additional 273,838 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LNTH. B. Riley dropped their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a report on Monday, June 23rd. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $131.20.

Lantheus Stock Performance

NASDAQ:LNTH opened at $71.19 on Friday. Lantheus Holdings, Inc. has a twelve month low of $69.12 and a twelve month high of $118.21. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average of $77.71 and a 200-day moving average of $88.13. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 20.22 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. Lantheus's revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.69 EPS. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.